不同血清诊断模型对肝纤维化的诊断价值
The Value of Serum Diagnostic Models in the Diagnosis of Hepatic Fibrosis
DOI: 10.12677/ACM.2021.113136, PDF,   
作者: 张 杰:青岛大学附属医院放射科,山东 青岛;张永军*:刁镇卫生院内科,山东 济南
关键词: 肝纤维化血清学指标血清诊断模型Hepatic Fibrosis Serological Indexes Serum Diagnostic Model
摘要: 目的:分析肝段切除患者术前的血清学指标并建立血清诊断模型,评价血清诊断模型对肝纤维化的应用价值。方法:回顾性收集我院2017年6月至2019年12月肝段切除患者术前的血清学指标,计算天冬氨酸转氨酶/血小板比值指数(aspartate aminotransferase to platelet ratio index, APRI)、γ谷氨酰转肽酶/血小板比值指数(γ-glutamyltranspeptidase to platelet ratio, GPR)、基于四因子的纤维化指数(fibrosis index based on the four factors, FIB-4)以及AST/ALT比值(AST/ALT ratio, AAR)四种肝纤维化诊断模型,使用ROC曲线评价每种诊断模型对≥S1、≥S2、≥S3以及≥S4四种肝纤维化分组的诊断能力。结果:APRI、GPR、FIB-4三种模型对于四种肝纤维化分组均有统计学意义,P值范围为(0.000~0.049),AAR对每种分组均没有意义。FIB-4模型诊断不同分期肝纤维化性能最佳,其中对于≥S1期肝纤维化诊断价值最大,AUC达0.960,以约登指数最大值计算临界值为0.850。结论:APRI、GPR、FIB-4三种血清诊断模型可以提示不同分期肝纤维化,FIB-4模型对≥S1期肝纤维化价值最佳。
Abstract: Objective: To analyze the preoperative serological indexes of patients with segmental hepatectomy and establish serum diagnostic models, and to evaluate the application value of serum diagnostic model in liver fibrosis. Methods: Serological indexes of patients undergoing segmental hepatectomy in our hospital from June 2017 to December 2019 were collected retrospectively. Four hepatic fibrosis diagnostic models of aspartate aminotransferase/platelet ratio index (APRI), gamma glutamyl transpeptidase/platelet ratio index (GPR), fibrosis index based on four factors (FIB-4) and AST/ALT ratio (AAR) were calculated. ROC curve was used to evaluate the diagnostic ability of each diagnostic model for ≥S1, ≥S2, ≥S3 and ≥S4 liver fibrosis groups. Results: The three models of APRI, GPR and FIB-4 had statistical significance for the four groups of liver fibrosis with the range of P value (0.000~0.049); AAR was not significant for each group. FIB-4 had the best diagnostic performance in different stages of liver fibrosis, in which the diagnostic value of ≥S1 stage was the highest with the AUC 0.960. The critical value calculated by the maximum value of Jordan index was 0.850. Conclusion: Three serum diagnostic models of APRI, GPR and FIB-4 can indicate different stages of liver fibrosis, and FIB-4 model is the best for ≥S1 stage of liver fibrosis.
文章引用:张杰, 张永军. 不同血清诊断模型对肝纤维化的诊断价值[J]. 临床医学进展, 2021, 11(3): 947-952. https://doi.org/10.12677/ACM.2021.113136

参考文献

[1] 陈宵瑜, 杨长青. 肝纤维化发生机制研究新进展[J]. 实用肝脏病杂志, 2016, 19(1): 121-124.
[2] 孙亚朦, 吴晓宁, 周家玲, 等. 慢性乙型肝炎肝纤维化逆转评估方法的探讨[J]. 中华肝脏病杂志, 2016, 24(7): 552-554.
[3] Sun, M. and Kisseleva, T. (2015) Reversibility of Liver Fibrosis. Clinics and Research in Hepatology and Gastroenterology, 39, S60-S63. [Google Scholar] [CrossRef] [PubMed]
[4] 丁德平, 刘平, 陈琳莉, 等. FibroScan、AAR、APRI、FIB-4及其联合应用对乙型肝炎患者肝纤维化程度诊断效价的意义[J]. 中西医结合肝病杂志, 2016, 26(5): 267-269+286.
[5] 张旭, 王煜, 马娟, 等. 5种无创诊断技术单独及联合应用对慢性乙型肝炎肝纤维化的诊断价值比较[J]. 临床肝胆病杂志, 2016, 32(10): 1888-1893.
[6] 陆伦根, 尤红, 谢渭芬, 等. 肝纤维化诊断及治疗共识(2019年) [J]. 临床肝胆病杂志, 2019, 6(10): 793-803.
[7] 秦雨萌, 陈胜华. 肝纤维化进程中细胞外基质对肝星状细胞的作用及机制研究进展[J]. 实用肝脏病杂志, 2017, 20(3): 381-384.
[8] Friedman, S.L. and Bansal, M.B. (2006) Reversal of Hepatic Fibrosis—Fact or Fantasy? Hepatology, 43, 82-88. [Google Scholar] [CrossRef] [PubMed]
[9] 张启迪, 陆伦根. 无创肝纤维化/肝硬化评估技术的现状[J]. 中华肝脏病杂志, 2018, 26(5): 325-327.
[10] Stibbe, K.J.M., Verveer, C., Francke, J., et al. (2011) Comparison of Non-Invasive Assessment to Diagnose Liver Fibrosis in Chronic Hepatitis B and C Patients. Scandinavian Journal of Gastroenterology, 46, 962-972. [Google Scholar] [CrossRef] [PubMed]
[11] 孔梦娟, 周贤, 罗小庆. ARFI与Fibroscan评估HCV肝纤维化诊断效能的Meta分析[J]. 浙江医学, 2019, 41(8): 795-801.
[12] 刘婷, 徐铭益. 肝纤维化的血清学诊断研究进展[J]. 实用肝脏病杂志, 2016, 19(1): 125-128.
[13] 李斌, 张鹏. 血清透明质酸、IV型胶原、单胺氧化酶及转化生长因子β1联合检测对肝纤维化的诊断价值分析[J]. 实用医院临床杂志, 2019, 16(5): 37-39.
[14] 柯柳, 刘志娟, 李俩, 等. 肝纤维化的诊断和评估技术研究进展[J]. 微创医学, 2020, 15(5): 660-664.
[15] Lemoine, M., Shimakawa, Y., Nayagam, S., et al. (2016) The Gamma-Glutamyl Transpeptidase to Platelet Ratio (GPR) Predicts Significant Liver Fibrosis and Cirrhosis in Patients with Chronic HBV Infection in West Africa. Gut, 65, 1369-1376. [Google Scholar] [CrossRef] [PubMed]
[16] Nakamura, Y., Fukuhara, T., Aikata, H., et al. (2017) Liver Fibrosis Assessment by FibroScan Compared with Pathological Findings of Liver Resection Specimen in Hepatitis C Infection. Hepatology Research, 48, 767-772. [Google Scholar] [CrossRef] [PubMed]
[17] Sonneveld, M.J., Brouwer, W.P., Chan, L.Y., et al. (2019) Optimisation of the Use of APRI and FIB-4 to Rule out Cirrhosis in Patients with Chronic Hepatitis B: Results from the SONIC-B Study. The Lancet Gastroenterology & Hepatology, 4, 538-544. [Google Scholar] [CrossRef